The Impact of De-implementing Urine Dipsticks for Diagnosis of UTIs in Hospitals

The Impact of De-implementing Urine Dipsticks for Diagnosis of Urinary Tract Infections in the North Denmark Region: An Interrupted Time-series Analysis

The goal of this interrupted time-series analysis is to evaluate the impact of the de-implementation of urine dipsticks as a diagnostic tool for urinary tract infections (UTIs) in hospitalized patients in the North Denmark Region. The main question it aims to answer is:

How does de-implementation of urine dipsticks affect the diagnosis and management of UTIs and related disorders?

Specifically, does it change the following parameters:

• Number and severity of UTI infections (lower and upper UTI, non-severe and severe)
• Antibiotic prescription (overall, antibiotic classes, administration routes, duration, dosages)
• Number of urine cultures and number of positive urine cultures
• Risks of admission to intensive care units and 30-day mortality
• Risk of drug toxicity
• Length of hospital stay
• Risk of admission to intensive care unit
• 30-day risk of readmission after discharge
• 6-month risks of Clostridioides difficile enterocolitis and de novo antimicrobial resistance in cultures obtained during routine clinical care.

Researchers hypothesize that de-implementing urine dipsticks will lead to a reduced frequency of diagnosed cystitis, reduced antibiotic use, and fewer urine cultures without negatively affecting patient mortality or readmission risk.

Researchers will compare the outcomes before and after the discontinuation of urine dipsticks across hospitals in the North Denmark Region. Furthermore, results will be compared to another Danish administrative healthcare region where dipsticks are still in use as well as urine culture data from the primary sector in the North Denmark Region.

Since this is a registry-based observational study utilizing data from the electronic patient record system in the North Denmark Region, no direct contact will be made with participants.

Study Overview

• Status: Not yet recruiting
• Conditions: Urinary Tract Infections; Urinalysis; Anti-Bacterial Agents; Clinical Decision-making; Point-of-Care Testing; Diagnostic Techniques and Procedures; Registry
• Intervention / Treatment: Other: Usual practice with no intervention; Diagnostic test: De-implementation of Urinary Dipsticks

Detailed Description

BACKGROUND:

Urinary tract infections (UTIs) are a leading cause of antibiotic treatment and hospitalizations in Europe and the United States. Urine dipsticks are a widely used point-of-care test in hospitals, with over half of admitted patients in the North Denmark Region being screened using this method. They are considered an effective tool to rule out UTIs and aim to save resources by reducing unnecessary urine cultures and guiding initial antibiotic choice when used correctly. However, for reliable results, urine dipsticks require specific preanalytical conditions, such as a clean midstream sample retained in the bladder for 4-6 hours before voiding. These criteria are rarely met in clinical practice. Moreover, the prevalence of asymptomatic bacteriuria among hospitalized patients is about 45% which requires careful interpretation and correlation with specific symptoms of UTI by the clinician.

Although designed to rule out UTIs, studies suggest that urine dipsticks are often misused to rule them in, despite their low positive predictive value in hospital settings. This misuse may contribute to excessive antibiotic use. Furthermore, despite their generally high negative predictive value, a recent study in the North Denmark Region found that negative dipsticks cannot reliably exclude UTIs in symptomatic patients.

Due to these limitations, urine dipsticks were de-implemented throughout the North Denmark Region in August 2023 and February 2024. In September 2024, the Danish Society of Infectious Diseases and the Danish Society of Clinical Microbiology recommended discontinuing dipstick use in all Danish hospitals. However, the impact of de-implementing such a widely used point-of-care test remains unknown, raising questions about whether the advantages of this decision outweigh its potential drawbacks.

AIM This study aims to assess the impact of removing urine dipsticks in hospitals in the North Denmark Region.

HYPOTHESES

1. The incidence of urine cultures will decrease after the de-implementation of the urine dipstick.
2. The incidence of the ICD-10 codes, DN300 (acute cystitis), DN308C (recurrent cystitis), DN309 (unspecific cystitis), and DA419B (urosepsis) will decrease after the de-implementation of the urine dipstick.
3. The overall use of antibiotics as well as UTI-specific antibiotics, pivmecillinam, nitrofurantoin, sulfamethizol, and trimethoprim, will decrease after the de-implementation of the urine dipstick.
4. Risk of admission into the intensive care unit will remain unchanged before and after the de-implementation of the urine dipstick.
5. The average length of hospital stay and mortality rate will remain unchanged before and after the de-implementation of the urine dipstick.
6. Risk of early readmissions, defined as a return to an inpatient unit or emergency room within 30 days after the initial discharge, will remain the same before and after the de-implementation of the urine dipstick.

In a subpopulation of patients with positive urine cultures, the investigators hypothesize that:

1. The mortality rate and average length of stay will remain unchanged after the de-implementation of the urine dipstick.
2. The proportion of patients treated with antibiotics with uropathogenic coverage will remain the same before and after the de-implementation of the dipsticks (the UTI-specific antibiotics presented above and/or ampicillin/gentamicin, piperacillin/tazobactam or ciprofloxacin).

METHODS Design This study will be a registry-based interrupted time-series analysis utilizing data from the Business Intelligence Portal in the North Denmark Region. Data before and after the abolishment of the dipsticks will be extracted.

Setting Exposure The de-implementation of urine dipsticks in North Denmark Region in August 2023 (Aalborg) and February 2024 (Hjørring).

Study period Data will be extracted from both emergency rooms and inpatient units. The data extraction will start when the Business Intelligence Portal can extract data (preferably from 2019), and end at the latest update of conducting the study.

This study will include two control groups:

1. A comparable hospital cohort from the Central Denmark Region.
2. The total number of urine cultures requested by general practitioners in the North Denmark Region during the study period.

STATISTICS To avoid duplicates, the primary analysis will only include each patient's first admission during the study period.

Descriptive statistics: Incidence rates

Since hospitalized patients are an open cohort, the incidence rates (e.g. of antibiotic use), will be calculated using the following formula:

Monthly incidence rate of pivmecillinam use=((Number of unique persons treated with pivmecillinam))/(Amount of total person time in a month)=X pr.1000 patient days

Confidence intervals of the incidence rates will be calculated based on the Poisson distribution, and the standard error will be calculated as:

Standard error (log⁡〖rate)=1/√(number of cases)〗 The total incidence rates will be standardized using direct standardization based on the age distribution of the patient population as of September 2024 (the latest available data at the time of writing this protocol).

Mortality

Mortality rates will be calculated using the same methodology as presented above. In a supplementary analysis, the investigators will calculate the 30-day mortality risk:

30-day mortality risk=(Number of deaths within 30 days)/(Total number of admissions)=X %

And the case-fatality rate:

Case fatality=(Number of deaths in the hospital)/(Total number of admissions)=X %

Charlson Severity Index The medical history extracted up to 10 years before the index date, will be extracted to calculate the Charlson Comorbidity Index using standard methodology.

Comparisons The incidence and mortality rates in the North Denmark Region before and after the de-implementation of the dipstick will be compared using the principles of interrupted time series regression. This methodology offers the advantage of adjusting for seasonality. Furthermore, the rates in the North Denmark Region will be compared to those in the control groups.

• Study Type: Observational
• Enrollment (Estimated): 480000

Contacts and Locations

• Study Contact: Name: Peter Preben Eggertsen, MD, PhD; Phone Number: +45 97660566; Email: p.eggertsen@rn.dk
• Study Contact Backup: Name: Jacob Bodilsen, MD, PhD; Phone Number: +45 97660566; Email: jacob.bodilsen@rn.dk

Study Locations

• Denmark
  • Aalborg, Denmark, 9000
    • Aalborg University Hospital
    • Contact: Jacob Bodilsen, MD, PhD; Phone Number: +45 97660566; Email: jacob.bodilsen@rn.dk
  • Hjørring, Denmark, 9800
    • North Denmark Regional Hospital
    • Contact: Peter Preben Eggertsen, MD, PhD; Phone Number: +45 97660566; Email: p.eggertsen@rn.dk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

A primary inclusion criterion is that adult patients (≥18 years of age) begin their admission in one of the four emergency rooms in the North Denmark Region. Three of these are part of Aalborg University Hospital, located in Hobro, Aalborg, and Thisted, while the fourth is at Hjørring, part of the North Denmark Regional Hospital. Patients arrive at the emergency rooms either through referrals from general practitioners or directly via emergency calls.

Following admission, patients may be discharged or transferred to an inpatient unit, including internal medicine, abdominal surgery, or urological surgery departments. Other surgical departments (e.g., orthopedic surgery), emergency rooms for orthopedic injuries ("skadestuer"), and pediatric departments (<18 years) are not included in this study.

Description

Inclusion Criteria:

• All patients admitted to emergency rooms (≥18 years) from 2019 and forward.

Exclusion Criteria:

• Patients directly admitted to an inpatient unit without first visiting an emergency room are excluded from the study.
• For the primary analysis, only the first admission will be included; subsequent admissions will be excluded.

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Emergency rooms in North Denmark Region; Data from all emergency rooms in North Denmark Region will be retrieved. This includes sites at Aalborg University Hospital and North Denmark Regional Hospital.	Diagnostic test: De-implementation of Urinary Dipsticks; In August 2023 / February 2024, urinary dipsticks were de-implemented in hospitals across the North Denmark Region. Using registry-based data, the investigators aim to evaluate the clinical impact of this decision.
Control urine cultures from general practice; The count of urine cultures ordered in the primary sector outside hospitals in the North Denmark Region (general practice), where dipsticks remain in use, will serve as a control.	Other: Usual practice with no intervention; In hospitals within the Central Denmark Region and in the primary care sector, urinary dipsticks have not been de-implemented and remain in use. Registry-based data from these settings will serve as a control.
Control hospital in Central Denmark Region; The investigators aim to retrieve data from a hospital outside the North Denmark Region that continues to use urine dipsticks. Specifically, the investigators plan to collect data from Aarhus University Hospital, the largest hospital in the Central Denmark Region.	Other: Usual practice with no intervention; In hospitals within the Central Denmark Region and in the primary care sector, urinary dipsticks have not been de-implemented and remain in use. Registry-based data from these settings will serve as a control.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Monthly Incidence Rate of Urinary Tract Diagnoses (Composite Measure)	The monthly count of urinary tract infection diagnoses (ICD-10 codes: DN300, DN308C, DN309, DA419B) will be divided by the total person-time contributed by all admitted patients to the hospitals. The resulting incidence rate will be expressed as the number of cases per 1000 patient-days.	The monthly incidence will be calculated between January 2019 to end of the study (September 2025)
Monthly Incidence Rate of Urine Cultures (Composite Measure)	The monthly count of urine cultures (including all cultures, both positive and negative) will be divided by the total person-time contributed by admitted patients. The resulting incidence rate will be expressed as the number of cases per 1000 patient-days.	The monthly incidence will be calculated between January 2019 to end of the study period (September 2025)
Monthly Incidence Rate of Antibiotic Usage (Composite Measure)	The monthly count of urinary tract infection-specific antibiotic use (pivmecillinam, nitrofurantoin, sulfamethizole, and trimethoprim) will be divided by the total person-time contributed by all admitted patients to the hospitals. The resulting incidence rate will be expressed as the number of cases per 1000 patient-days.	The monthly incidence rate will be calculated between January 2019 to end of the study period (September 2025)
Monthly Mortality Rate (Composite Measure)	The monthly count of deaths will be divided by the total person-time contributed by admitted patients. The resulting mortality rate will be expressed as the number of deaths per 1000 patient-days.	The monthly mortality rate will be calculated between January 2019 to end of the study period (September 2025)
Monthly Incidence Rate of Readmissions (Composite Measure)	The monthly count of readmissions, defined as a return to an inpatient unit or emergency room within 30 days after the initial discharge, will be divided by the total person-time contributed by admitted patients. The resulting incidence rate will be expressed as the number of readmissions per 1000 patient-days.	The monthly incidence rate of readmissions will be calculated between January 2019 and the end of the study period (September 2025)
Median Length of Hospital Stay	The length of hospital stay will be measured in days for each admitted patient. The monthly median and interquartile range will be calculated over the study period.	The monthly median will be calculated from January 2019 to the end of the study period (September 2025).

Collaborators and Investigators

• Sponsor: Jacob Bodilsen

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2025
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: December 20, 2024
• First Submitted That Met QC Criteria: December 20, 2024
• First Posted (Actual): December 27, 2024

Study Record Updates

• Last Update Posted (Estimated): October 1, 2025
• Last Update Submitted That Met QC Criteria: September 30, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Keywords: Hospital; Urinary Tract Infections; Urine Dipstick De-implementation; Registry-Based Study; Clinical Impact; urine dipsticks
• Additional Relevant MeSH Terms: Urogenital Diseases; Male Urogenital Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Infections; Urinary Tract Infections
• Other Study ID Numbers: De-implementing Dipsticks

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: By Danish law, individual registry-based data cannot be shared. However, anonymized and aggregated composite data may be shared upon request.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No